 | Up a level |
Digklia, A; Kollár, A; Dietrich, D; Kronig, M N; Britschgi, C; Rordorf, T; Joerger, M; Krasniqi, F; Metaxas, Y; Colombo, I; Ribi, K; Rothermundt, C (2024). SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. European journal of cancer, 197(113470), p. 113470. Elsevier 10.1016/j.ejca.2023.113470
Greiner-Perth, R; Sellhast, N; Perler, G; Dietrich, D; Staub, L P; Röder, C (2016). Erratum to: Dynamic posterior stabilization for degenerative lumbar spine disease: a large consecutive case series with long-term follow-up by additional postal survey. European spine journal, 25(8), p. 2571. Springer 10.1007/s00586-016-4600-7
Greiner-Perth, R; Sellhast, N; Perler, G; Dietrich, D; Staub, L; Röder, C (2016). Dynamic posterior stabilization for degenerative lumbar spine disease: a large consecutive case series with long-term follow-up by additional postal survey. European spine journal, 25(8), pp. 2563-2570. Springer 10.1007/s00586-016-4532-2
Koeberle, D; Betticher, D C; von Moos, R; Dietrich, D; Brauchli, P; Baertschi, D; Matter, K; Winterhalder, R; Borner, M; Anchisi, S; Moosmann, P; Kollár, Attila; Saletti, P; Roth, A; Frueh, M; Kueng, M; Popescu, R A; Schacher, S; Hess, V and Herrmann, R (2015). Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of oncology, 26(4), pp. 709-714. Oxford University Press 10.1093/annonc/mdv011
Röder, C; Staub, L; Dietrich, D; Zweig, T; Melloh, M; Aebi, M (2009). Benchmarking with Spine Tango: potentials and pitfalls. European spine journal, 18 Suppl 3(Suppl 3), pp. 305-311. Berlin: Springer-Verlag 10.1007/s00586-009-0943-7
Borner, M; Koeberle, D; Von Moos, R; Saletti, P; Rauch, D; Hess, V; Trojan, A; Helbling, D; Pestalozzi, B; Caspar, C; Ruhstaller, T; Roth, A; Kappeler, A; Dietrich, D; Lanz, D; Mingrone, W (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology, 19(7), pp. 1288-92. Oxford: Oxford University Press 10.1093/annonc/mdn058
Herrmann, R; Bodoky, G; Ruhstaller, T; Glimelius, B; Bajetta, E; Schüller, J; Saletti, P; Bauer, J; Figer, A; Pestalozzi, B; Köhne, CH; Mingrone, W; Stemmer, SM; Tàmas, K; Kornek, GV; Koeberle, D; Cina, S; Bernhard, J; Dietrich, D; Scheithauer, W; ... (2007). Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of clinical oncology, 25(16), pp. 2212-7. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2006.09.0886
Leyvraz, S; Herrmann, R; Guillou, L; Honegger, HP; Christinat, A; Fey, MF; Sessa, C; Wernli, M; Cerny, T; Dietrich, D; Pestalozzi, B; Swiss, Group for Clinical Cancer Research (SAKK) (2006). Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. British journal of cancer, 95(10), pp. 1342-7. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6603420
Leyvraz, S; Zweifel, M; Jundt, G; Lissoni, A; Cerny, T; Sessa, C; Fey, M; Dietrich, D; Honegger, HP; Swiss, Group for Clinical Cancer Research (2006). Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Annals of oncology, 17(4), pp. 646-51. Oxford: Oxford University Press 10.1093/annonc/mdl020
Röder, C; Staub, L P; Eichler, P; Widmer, M; Dietrich, D; Eggli, S; Müller, U (2006). Avoiding misclassification bias with the traditional Charnley classification: rationale for a fourth Charnley class BB. Journal of orthopaedic research, 24(9), pp. 1803-8. Hoboken, N.J.: Wiley 10.1002/jor.20224
Scheurer, E; Ith, M; Dietrich, D; Kreis, R; Hüsler, J; Dirnhofer, R; Boesch, C (2005). Statistical evaluation of time-dependent metabolite concentrations: estimation of post-mortem intervals based on in situ 1H-MRS of the brain. NMR in biomedicine, 18(3), pp. 163-72. London: Wiley Interscience 10.1002/nbm.934
